hero bg

Delivering the promise of cancer immunotherapy

Enterome is a clinical stage company developing off-the-shelf, transformational cancer treatments targeting all tumor types. Ongoing Phase 2 trials for our most advanced programs EO2401 and EO2463 have shown promising efficacy in recurrent glioblastoma, in adrenal tumors and in Non-Hodgkin lymphoma, with good safety in more than 200 patients.

Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T cells, overcoming the immune tolerance to self-antigens. Watch our video here

With 4 clinical immune-oncology projects to date, our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression “from bench to bedside”. In addition to OncoMimics™ programs, Enterome has also established a partnership with Nestlé Health Science in inflammatory diseases and food allergy.

Database of 20+ millions unique full length and functional proteins from the gut microbiome

Specifically designed Mimicry drug discovery platform to decipher this database

Three transformative drug pipelines targeting cancer, inflammatory diseases and allergies

A new class of therapeutics poised to improve human health

Enterome France

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex